Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Celadon confident in seeing through funding challenges
(Sharecast News) - Cannabis-based medicines specialist Celadon Pharmaceuticals updated the market on its financial position on Friday, amid ongoing challenges related to delays in expected funding. The AIM-traded company had anticipated raising £2.1m through an equity fundraising round announced on 10 May, with shares issued in four tranches.
To date, Celadon said it had received £0.6m of the £1m committed by one investor, but the delay in receiving the £0.1m due from the third tranche had led to the postponement of the fourth tranche, worth £0.25m.
The investor had reiterated their intention to fulfil the outstanding payment obligations, but Celadon said the timeline remained uncertain.
Additionally, Celadon said it had faced delays in accessing funds from its committed credit facility.
An initial drawdown request for £1m, submitted on 27 June, had only partially materialised, with £0.3m received as of 22 August.
The remaining £0.7m was expected following the completion of a property transaction, according to the lender.
Despite the delays, the company's directors said they were confident in securing the remaining funds.
As of 22 August, Celadon's cash reserves stood at £0.21m - a figure that could improve upon the receipt of the outstanding equity and credit facility funds.
However, the company's continued operations depended on the timely arrival of those funds or alternative financing, which was yet to be secured.
The board said it was also exploring longer-term debt facilities with potential institutional lenders to refinance the existing credit arrangements.
Celadon said it would provide further updates as the situation progresses.
"Celadon is grateful to the investor and lender for their re-confirmed commitments to the Company and for the additional funds received from the lender," said chief executive officer James Short.
"The group's ongoing conversations with alternative potential lenders continue to progress positively with a view to securing the long-term future for the business."
At 1130 BST, shares in Celadon Pharmaceuticals were up 31.27% at 28.88p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.